IS TOLVAPTAN A PROTECTIVE AGENT FOR CARDIAC INSUFFICIENCY IN PERITONEAL DIALYSIS PATIENTS?A META-ANALYSIS.

Back

E-Poster

https://storage.unitedwebnetwork.com/files/1099/562a9afc495fb2765603945756c56e51.pdf

Abstract Title

First Name *

Stylianou

Last Name *

Konstantinos

Co-author 1

THEODORA OIKONOMAKI dora.oikonomaki@gmail.com EVAGGELISMOS GENERAL HOSPITAL OF ATHENS PIRAEUS

Co-author 2

Co-author 3

Co-author 4

Co-author 5

Co-author 6

Co-author 7

Co-author 8

Co-author 9

Co-author 10

Co-author 11

Co-author 12

Co-author 13

Co-author 14

Co-author 15

Introduction

Peritoneal dialysis is an effective renal replacement therapy that offers a longer preservation of the residual renal function, a better blood pressure regulation and quality of life. The use of diuretics is safe and beneficial but sometimes ineffective.

Methods

With this meta-analysis, was investigated the possible beneficial role of tolvaptan in the body fluid control and the management of heart failure markers (LVMI, BNP) in individuals undergoing peritoneal dialysis.

Results

Conclusions

Tolvaptan as an adjuvant therapy appears to be useful on the volume control and potentially improve the cardiac function. More high-quality studies are required.

E-Poster Format Requirements

PDF file
Layout: Portrait (vertical orientation)
One page only (Dim A4: 210 x 297mm or PPT)
E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
File Size: Maximum file size is 2 Megabytes (2 MB)
No hyperlinks, animated images, animations, and slide transitions
Language: English
Include your abstract number
E-posters can include QR codes, tables and photos